Endoscopy 2002; 34(7): 524-526
DOI: 10.1055/s-2002-33230
Original Article
© Georg Thieme Verlag Stuttgart · New York

Differences in the Diagnostic Yield of Upper Gastrointestinal Endoscopy in Dyspeptic Patients Receiving Proton-Pump Inhibitors and H2-Receptor Antagonists

R.  M. S.  Mitchell 1 , J.  S. A.  Collins 2 , R.  G. P.  Watson 2 , T.  C. K.  Tham 3
  • 1Dept. of Gastroenterology, Belfast City Hospital, Belfast, Northern Ireland, United Kingdom
  • 2Dept. of Medicine, Institute of Clinical Science, Royal Victoria Hospital, Belfast, Northern Ireland, United Kingdom
  • 3Ulster Hospital, Belfast, Northern Ireland, United Kingdom
Further Information

Publication History

Submitted 7 April 2000

Accepted after Revision 21 February 2002

Publication Date:
12 August 2002 (online)

Background and Study Aims: Patients attending for diagnostic oesophagogastroduodenoscopy (OGD) for dyspeptic symptoms are often receiving acid-suppression therapy that has not been discontinued prior to endoscopy, and this may reduce the diagnostic yield of endoscopy. The aim of this study was to compare the diagnostic yield of OGD in uncomplicated dyspepsia in patients receiving no medication, those receiving acid-suppression therapy, and those receiving nonsteroidal anti-inflammatory drugs (NSAIDs) at the time of endoscopy.
Patients and Methods: A total of 6825 diagnostic OGDs performed in our unit between 1993 and 2001 were analysed. Patients were excluded if they had sinister symptoms, were receiving NSAIDs, or were undergoing repeat or surveillance endoscopy.
Results: A total of 4233 OGDs (62 %) fulfilled the criteria for uncomplicated dyspepsia. Of the patients examined in these procedures, 1367 (32 %) were receiving acid-suppression therapy. A total of 724 patients (53 % of those on therapy) were receiving proton-pump inhibitors (PPIs), 393 of whom (54 %) had positive endoscopic findings (oesophagitis 31 %, gastritis 16 %, duodenal ulcer/duodenitis 16 %). A total of 643 (47 % of the patients on therapy) were receiving H2-receptor antagonists, 443 of whom (69 % of this group) had positive endoscopic findings (oesophagitis 30 %, gastritis 21 %, duodenal ulcer/duodenitis 31 %). A total of 2866 patients were not receiving acid-suppression therapy, 1805 of whom (63 %) had endoscopic findings (oesophagitis 37 %, gastritis 14 %, duodenal ulcer/duodenitis 24 %). The endoscopic yield was significantly lowest in the PPI group, except for the diagnosis of oesophagitis. Overall, 17 carcinomas were detected in patients referred with simple dyspepsia, and in five of these cases the patients were receiving acid suppression.
Conclusions: The widespread use of acid suppression in the treatment of simple dyspepsia prior to endoscopy leads to a reduction in the endoscopic recognition of mucosal lesions caused by acid-peptic disease, but not to a high healing rate for these lesions, and it may mask malignancy.

References

  • 1 Bodger K, Daly M J, Heatley R V. Prescribing patterns for dyspepsia in primary care: a prospective study of selected general practitioners.  Aliment Pharmacol Ther. 1996;  10 889-895
  • 2 Roberts S J, Bateman D N. Prescribing of antacids and ulcer healing drugs in primary care in the north of England.  Aliment Pharmacol Ther. 1995;  9 137-143
  • 3 Thors H, Sigurdsson H, Oddson E, Thjodleifsson B. Survey of prescription for peptic ulcer drugs (ACT class AOB2) in Iceland.  Scand J Gastroenterol. 1994;  29 988-994
  • 4 Tham T CK, Johnston S D, Watson R GP. Patient knowledge and prescription of ulcer healing drugs in medical inpatients.  Br J Clin Pharmacol. 1995;  39 197-200
  • 5 Health and Public Policy Committee, American College of Physicians. Endoscopy in the evaluation of dyspepsia.  Ann Intern Med. 1985;  102 266-269
  • 6 British Society of Gastroenterology. Dyspepsia management guidelines. London; British Society of Gastroenterology, (http://www.bsg.org.uk/pdf_word_docs/dyspepsia.pdf) 1996
  • 7 Bramble M G, Suvakovic Z, Hungin A P. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy.  Gut. 2000;  46 464-467
  • 8 Cooperative Study Group. Double blind comparative study of omeprazole and ranitidine in patients with duodenal or gastric ulcer: a multicentre trial.  Gut. 1990;  31 653-656
  • 9 Valenzuela J E, Berlin R G, Snape W J. et al . U.S. experience with omeprazole in duodenal ulcer: multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.  Dig Dis Sci. 1991;  36 761-768
  • 10 Mansfield J C, Greenaway J R, Contractor B R. et al . Open access gastroscopy findings are unrelated to the use of aspirin and non-steroidal anti-inflammatory drugs.  Br J Gen Pract. 1997;  47 825-826
  • 11 Voutilainen M, Sipponen P, Meeklin J P. et al . Gastro-esophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1 128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms.  Digestion. 2000;  61 6-13

R. M. S. Mitchell, M.B., M.R.C.P.

Duke University Medical Center

Box 3189 · Durham, NC 27710 · USA ·

Fax: + 1-919-684-4695

Email: michael_mitchell@talk21.com